Fig. 5: Post-treatment with caPAK4 shows a therapeutic effect in the α-synuclein PD model. | Cell Death & Disease

Fig. 5: Post-treatment with caPAK4 shows a therapeutic effect in the α-synuclein PD model.

From: p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1

Fig. 5: Post-treatment with caPAK4 shows a therapeutic effect in the α-synuclein PD model.The alternative text for this image may have been generated using AI.

A Experimental scheme. B Representative images of TH immunostaining in the SN from lenti-Ctrl- or lenti-caPAK4-injected rats post AAV-hα-syn. C Stereological counting of TH-positive and Nissl-stained dopamine neurons (n = 5 for each group). D Representative images of TH immunostaining in the rat striatum. E Quantification of striatal TH-positive fiber density (n = 5 for each group). F Quantification of cumulative amphetamine-induced ipsilateral rotations (n = 5 for each group). G Quantification of dopamine levels in the ipsilateral striatum from lenti-Ctrl- or lenti-caPAK4-injected rats post AAV-hα-syn (n = 5 for each group). The data are presented as the mean ± SEM. *P < 0.01. Unpaired Student’s t test.

Back to article page